Catherine Del Vecchio Fitz
Overview
Explore the profile of Catherine Del Vecchio Fitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kabarriti R, Lloyd S, Jabalee J, Del Vecchio Fitz C, Tao R, Slater T, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857955
Background: The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% of cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be...
2.
Hanna G, Jabalee J, Lukens J, Sun L, Rettig E, Ferrandino 2nd R, et al.
Oral Oncol
. 2024 Aug;
158:107002.
PMID: 39159525
Background: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Testing for plasma tumor tissue modified viral (TTMV)-HPV DNA has emerged as a biomarker strategy for post-treatment...
3.
Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance
Roof S, Jabalee J, Rettig E, Chennareddy S, Ferrandino 2nd R, Chen S, et al.
Oral Oncol
. 2024 Jun;
155:106874.
PMID: 38878355
Objectives: Clinical and imaging examinations frequently have indeterminate results during cancer surveillance, which can lead to overtreatment and cause psychological and financial harm to the patient. This study addresses the...
4.
Huffman B, Singh H, Ali L, Horick N, Wang S, Hoffman M, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38272561
Background: Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed....
5.
Batool S, Sethi R, Wang A, Dabekaussen K, Egloff A, Del Vecchio Fitz C, et al.
Oral Oncol
. 2023 Oct;
147:106584.
PMID: 37837735
Objectives: While survival outcomes are favorable for Human Papillomavirus (HPV)-positive oropharyngeal squamous cell carcinomas (OPSCCs), early diagnosis may minimize treatment-related morbidity and mortality. This study evaluated circulating tumor tissue-modified viral...
6.
Hanna G, Roof S, Jabalee J, Rettig E, Ferrandino R, Chen S, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4306-4313.
PMID: 37566241
Purpose: Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Consensus guidelines recommend clinical exams and imaging in decreasing frequency as part of posttreatment surveillance for recurrence....
7.
Rettig E, Waterboer T, Sim E, Faden D, Butt J, Hanna G, et al.
Oral Oncol
. 2023 May;
141:106417.
PMID: 37148655
No abstract available.
8.
Gunning A, Kumar S, Williams C, Berger B, Naber S, Gupta P, et al.
Diagnostics (Basel)
. 2023 Feb;
13(4).
PMID: 36832208
The NavDx blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a...
9.
Keller R, Mazor T, Sholl L, Aguirre A, Singh H, Sethi N, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200342.
PMID: 36634297
Purpose: With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape...
10.
Klein H, Mazor T, Siegel E, Trukhanov P, Ovalle A, Del Vecchio Fitz C, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):69.
PMID: 36202909
Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs...